Fair Value Measurements - Narrative (Details)			1 Months Ended	12 Months Ended
	Apr. 29, 2022 $ / shares shares	Dec. 09, 2021 day $ / shares shares	Apr. 30, 2023 USD ($) shares	Dec. 31, 2023 USD ($) day d $ / shares shares	Dec. 31, 2022 USD ($)	Oct. 27, 2023 USD ($) shares	Sep. 04, 2021 $ / shares	Jul. 22, 2021 shares
Cash and Cash Equivalents [Line Items]
Purchase of warrants (in shares) | shares				666,515				666,516
Expected term (in years)				5 years
Target share price of warrants or rights for redemption (in dollars per share) | $ / shares				$ 594.00
Redemption price per warrant (in dollars per share) | $ / shares				$ 0.33
Number of days for written notice of redemption | d				30
Minimum number of trading days | d				30
Change in fair value of warrants and contingent liabilities					$ (10,200,000)
Contingent consideration				$ 0	0
Total stock-based compensation expense				(326,000)	41,975,000
Outstanding loan balance				56,250,000
Current portion of long-term debt				$ 497,000	4,750,000
Restricted Stock Units (RSUs)
Cash and Cash Equivalents [Line Items]
Restricted stock units granted (in shares) | shares				1,836,177
Class A Common Stock Equals Or Exceeds Threshold One
Cash and Cash Equivalents [Line Items]
Minimum number of trading days | d				20
Consecutive trading day threshold | d				30
Public Warrants
Cash and Cash Equivalents [Line Items]
Purchase of warrants (in shares) | shares				452,272				447,223
Private Placement Warrants
Cash and Cash Equivalents [Line Items]
Purchase of warrants (in shares) | shares				214,243				219,293
Perceptive warrant liability
Cash and Cash Equivalents [Line Items]
Warrant liabilities				$ 2,500,000
Credit Agreement | Secured Debt
Cash and Cash Equivalents [Line Items]
Expected term (in years)						10 years
Revolving credit facility						$ 75,000,000
Credit Agreement | Secured Debt | Perceptive warrant liability
Cash and Cash Equivalents [Line Items]
Number of shares to purchase (in shares) | shares						1,200,000
Common Class A
Cash and Cash Equivalents [Line Items]
Purchase of aggregate private placement warrants (in shares) | shares				1
Warrant exercise price (in dollars per share) | $ / shares							$ 379.50
Target share price of warrants or rights for redemption (in dollars per share) | $ / shares				$ 330.00
Minimum number of trading days | day				20
Consecutive trading day threshold | day				30
Common stock threshold, number of trading days before notice of redemption | day				3
Redemption on warrant holders (in dollars per share) | $ / shares				$ 594.00
Common Class A | Class A Common Stock Equals Or Exceeds Threshold One
Cash and Cash Equivalents [Line Items]
Minimum threshold price of common stock specified to send notice of redemption to the warrant holders (in dollars per share) | $ / shares				594.00
Common Class A | Class A Common Stock Equals Or Exceeds Threshold Two
Cash and Cash Equivalents [Line Items]
Target share price of warrants or rights for redemption (in dollars per share) | $ / shares				330.00
Redemption price per warrant (in dollars per share) | $ / shares				$ 3.30
Number of days for written notice of redemption | day				30
Minimum
Cash and Cash Equivalents [Line Items]
Maturity, at amortized cost				$ 12,600,000
Maximum
Cash and Cash Equivalents [Line Items]
Maturity, at amortized cost				17,200,000
GeneDx
Cash and Cash Equivalents [Line Items]
Change in fair value of warrants and contingent liabilities				900,000
Number of shares holder (in shares) | shares			701,460
Business combination, contingent consideration arrangements				37,500,000	150,000,000
Business combination contingent consideration milestone payment for first year			$ 112,500,000
Business combination contingent consideration liability period 1				163,000,000
Business combination contingent consideration liability period 2				$ 219,000,000
Business combination contingent consideration first milestone percentage				80.00%
Business combination contingent consideration revenue target of milestone event				100.00%
Business combination contingent consideration percentage of milestone payment based on revenue target				100.00%
GeneDx | Private Placement Warrants
Cash and Cash Equivalents [Line Items]
Change in fair value of warrants and contingent liabilities				$ (200,000)	(21,100,000)
GeneDx | Contingent Consideration, Milestone Two
Cash and Cash Equivalents [Line Items]
Contingent consideration				0
Business combination, contingent consideration arrangements				$ 37,500,000
GeneDx | Common Class A
Cash and Cash Equivalents [Line Items]
Number of shares holder (in shares) | shares	2,400,000			701,460
Public per share (in dollars per share) | $ / shares	$ 160.38
Price per shares (in dollars per share) | $ / shares	$ 70.95			$ 160.38
GeneDx | Minimum
Cash and Cash Equivalents [Line Items]
Business combination contingent consideration revenue target of milestone event				90.00%
Sema4 OpCo, Inc
Cash and Cash Equivalents [Line Items]
Number of shares holder (in shares) | shares				576,412
Sema4 OpCo, Inc | Restricted Stock Units (RSUs)
Cash and Cash Equivalents [Line Items]
Restricted stock units granted (in shares) | shares		81,819
Total stock-based compensation expense				$ 800,000
Sema4 OpCo, Inc | Restricted Stock Units (RSUs) | Triggering Event I
Cash and Cash Equivalents [Line Items]
Public per share (in dollars per share) | $ / shares		$ 429
Sema4 OpCo, Inc | Restricted Stock Units (RSUs) | Triggering Event II
Cash and Cash Equivalents [Line Items]
Minimum number of trading days | day		20
Consecutive trading day threshold | day		30
Public per share (in dollars per share) | $ / shares		$ 495
Sema4 OpCo, Inc | Restricted Stock Units (RSUs) | Triggering Event III
Cash and Cash Equivalents [Line Items]
Public per share (in dollars per share) | $ / shares		$ 594
Level 2 | DECD Loan Agreement
Cash and Cash Equivalents [Line Items]
Outstanding loan balance				6,300,000	$ 6,300,000
Current portion of long-term debt				500,000
Carrying value				$ 5,000,000